Dx Shop Upstream Biosciences Inks Option to Acquire Pacific Pharma | GenomeWeb
NEW YORK (GenomeWeb News) – Upstream Biosciences yesterday said it has signed an option to buy Pacific Pharma Technologies, a company focused on drug development for parasitic diseases.
 
Upstream Biosciences, which develops genetic diagnostics for cancer and for predicting drug responses, said the agreement gives it an exclusive 3-month option to negotiate terms of the acquisition.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.